drugset / Trial / NCT01275157

Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects

NCT01275157

Phase 1 Completed 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-label

Summary

This is a single dose study of radiolabeled \[14C\]-LY2452473 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY2452473. This study is for research purposes only and is not intended to treat any medical condition.

Timeline

Start
2011-01
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2452473 Small molecule 15 mg Oral

Indications

No indication recorded.